Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks
American Journal of Clinical Dermatology · 2025
DOI: 10.1007/s40257-025-00975-3 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Clinical Dermatology, 2025. Verfasst von Alan D Irvine und 21 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Medicine, Trinity College Dublin, Dermatology, Children's Health Ireland at Crumlin, Dublin 12, Ireland. irvinea@tcd.ie. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Heterocyclic Compounds, 3-Ring, Janus Kinase Inhibitors. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie.
Abstract (Originalsprache)
BACKGROUND: Upadacitinib is an oral selective Janus kinase inhibitor approved to treat moderate-to-severe atopic dermatitis (AD) in adults and adolescents; long-term efficacy and safety data beyond 1 year are needed. OBJECTIVE: The aim was to evaluate the long-term efficacy and safety of upadacitinib treatment through 140 weeks in patients with moderate-to-severe AD. METHODS: Measure Up 1 (MeUp1; NCT03569293), Measure Up 2 (MeUp2; NCT03607422), and AD Up (NCT03568318) are ongoing, phase 3, randomized clinical trials evaluating upadacitinib 15 mg (UPA15) and 30 mg (UPA30) in adults and adolescents with moderate-to-severe AD. This interim analysis evaluated efficacy and safety through week 140. At baseline, patients were randomized 1:1:1 to receive once-daily UPA15, UPA30, or placebo alone (MeUp1/2) or with concomitant topical corticosteroids (AD Up). At week 16, patients initially randomized to placebo were rerandomized 1:1 to UPA15 or UPA30. Skin and itch efficacy assessments included achievement of ≥ 75%/≥ 90%/100% improvement from baseline in Eczema Area and Severity Index (EASI 75/90/100), validated Investigator Global Assessment for AD score of clear/almost clear (vIGA-AD 0/1), and ≥ 4-point improvement from baseline in Worst Pruritus Numerical Rating Scale (∆WP-NRS≥4). Safety assessments included incidence of treatment-emergent adverse events. RESULTS: A total of 2782 patients were randomized in MeUp1/2 or AD Up. Efficacy response rates, including optimal outcomes such as EASI 90 and WP-NRS score of 0/1, were sustained through week 140 in all three studies. At week 140, EASI 75 was achieved by 85.5%/90.5% (UPA15/UPA30; integrated MeUp1/2) and 81.5%/90.0% (UPA15/UPA30; AD Up) of patients, and vIGA-AD 0/1 was achieved by 56.6%/64.4% (UPA15/UPA30; integrated MeUp1/2) and 52.0%/56.8% (UPA15/UPA30; AD Up) of patients. Over 60% of patients across all three studies achieved ∆WP-NRS≥4 at week 140. Pooled safety data across all three studies demonstrated safety profiles consistent with 16-week and 52-week analyses. CONCLUSIONS: UPA15 and UPA30 with and without topical corticosteroids demonstrated robust, durable efficacy and a favorable safety profile through 140 weeks in adults and adolescents with moderate-to-severe AD. TRIAL REGISTRATION: Measure Up 1 (NCT03569293; https://clinicaltrials.gov/study/NCT03569293 ), Measure Up 2 (NCT03607422; https://clinicaltrials.gov/study/NCT03607422 ), and AD Up (NCT03568318; https://clinicaltrials.gov/study/NCT03568318 ).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Medicine, Trinity College Dublin, Dermatology, Children's Health Ireland at Crumlin, Dublin 12, Ireland. irvinea@tcd.ie.
- Division of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada.
- Section of Community Pediatrics, Department of Pediatrics, University of Calgary, Calgary, AB, Canada.
- Section of Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, AB, Canada.
- Dermatology Research Institute, Calgary, AB, Canada.
- Skin Health & Wellness Centre, Calgary, AB, Canada.
Förderung
- AbbVie
Zitieren
APA
Irvine, A. D., Prajapati, V. H., Guttman-Yassky, E., Simpson, E. L., Papp, K. A., Blauvelt, A., Chu, C. Y., Hong, H. C., Gold, L. F. S., de Bruin-Weller, M., Bieber, T., Kabashima, K., Rosmarin, D., Sancho, C., Calimlim, B. M., Grada, A., Yang, Y., Wu, X., Levy, G., …, & Silverberg, J. I. (2025). Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks. American Journal of Clinical Dermatology. https://doi.org/10.1007/s40257-025-00975-3
Vancouver
Irvine AD, Prajapati VH, Guttman-Yassky E, Simpson EL, Papp KA, Blauvelt A, et al. Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks. American Journal of Clinical Dermatology. 2025. doi:10.1007/s40257-025-00975-3
BibTeX
@article{Irvine2025,
author = {Irvine, Alan D and Prajapati, Vimal H and Guttman-Yassky, Emma and Simpson, Eric L and Papp, Kim A and Blauvelt, Andrew and Chu, Chia-Yu and Hong, H Chih-Ho and Gold, Linda F Stein and de Bruin-Weller, Marjolein and Bieber, Thomas and Kabashima, Kenji and Rosmarin, David and Sancho, Cristina and Calimlim, Brian M and Grada, Ayman and Yang, Yang and Wu, Xiaoqiang and Levy, Gweneth and Raymundo, Eliza M and Teixeira, Henrique D and Silverberg, Jonathan I},
title = {Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks},
journal = {American Journal of Clinical Dermatology},
year = {2025},
doi = {10.1007/s40257-025-00975-3}
}
EUVIMED